What is Versavo?

Versavo is a biosimilar bevacizumab and is indicated for the treatment of multiple cancers. It is used in combination with other chemotherapy drugs to treat cervical, colorectal, glioblastoma and non-squamous non-small cell lung cancer.

Storage Conditions

2-8 degrees Celsius (refrigerate),Do not freeze.

Presentation

Vial containing concentrate for solution for infusion.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

Metastatic Colorectal Cancer (mCRC):

mCRC is a stage of colorectal cancer where it spreads beyond the colon or rectum to other parts of the body, often requiring aggressive treatment for better survival.

How Bevacizumab works?

Mechanism of Action

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Our News, Stories, and Insights

rituximab
  • News
  • 29-07-2024

Dr. Reddy's rituximab biosimilar ituxredi gets EMA CHMP positive recommendation

  • News
  • 28-06-2024

Pertuzumab is a biosimilar medicine from Dr. Reddy's

  • Article
  • 20-06-2020

Qualification of a specific, sensitive and target tolerant method to quantitate free tocilizumab in human serum: Application to clinical studies with intravenous or subcutaneous administration

  • Article
  • 10-09-2022

Development and validation of a specific and sensitive method for detection of anti-tocilizumabantibodies in human serum in presence of high concentrations of drug and target.